Melanoma
eTheRNA is developing an mRNA-based vaccine against metastatic melanoma consisting of naked mRNA encoding for TriMix and 5 tumor-associated antigens that is being administered intranodally (injected into the patient’s lymph nodes).
HPV+ cancer
eTheRNA is developing an mRNA-based vaccine against HPV+ Head and neck cancer consisting of mRNA encoding for TriMix and E6/E7 antigens packaged in lipid nanoparticles administered intravenously.
Currently, a candidate is being tested in preclinical studies.
Kidney cancer
eTheRNA, in collaboration with Frame Therapeutics, is developing a mRNA-based vaccine against kidney cancer consisting of mRNA encoding for TriMix and frame shift neo-antigens packaged in lipid nanoparticles that will be administered intravenously.
Other indications
Antigens in both the intranodal and intravenous products are interchangeable. By replacing the antigens, a range of oncology indications could be targeted. The technology is available for partnering and collaboration (see partnership page).
Galileilaan 19, 2845 Niel, Belgium
+32 3 369 17 40
© 2020 Etherna | Studio Hanswijk
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.